<p>Sight Sciences, Inc.（纳斯达克代码：SGHT - 获取免费报告）在目前覆盖该公司的八位分析师中获得了一致的 “持有” 推荐，Marketbeat Ratings 报告称。一位投资分析师对该股票给予了卖出推荐，三位分析师给予了持有推荐，四位分析师对该公司发布了买入推荐。在过去一年中，发布报告的券商对该股票的平均十二个月目标价为 8.30 美元。</p>
<p>获取 <strong>Sight Sciences</strong> 的提醒：</p>
<p>几家券商已对 SGHT 发布了报告。瑞银集团将 Sight Sciences 的目标价从 7.00 美元上调至 12.00 美元，并在 12 月 23 日的研究报告中给予该公司 “买入” 评级。花旗集团将 Sight Sciences 的目标价从 5.50 美元上调至 9.10 美元，并在 12 月 11 日的研究报告中给予该公司 “中性” 评级。Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 Sight Sciences 的 “卖出（e+）” 评级。摩根士丹利在 12 月 2 日的研究报告中将 Sight Sciences 的目标价从 6.00 美元上调至 8.00 美元，并给予该股票 “等权重” 评级。最后，Lake Street Capital 在 10 月 21 日的研究报告中将 Sight Sciences 的目标价从 5.00 美元上调至 7.00 美元，并给予该股票 “买入” 评级。</p>
<p><strong>阅读我们关于 Sight Sciences 的最新报告</strong></p>
<h2>内部买卖</h2>
<p>在其他消息中，执行副总裁 Brenton Taylor 于 11 月 17 日星期一出售了 14,418 股公司的股票。股票以平均价格 7.06 美元出售，总交易额为 101,791.08 美元。交易后，这位执行副总裁直接持有公司 170,831 股股票，价值 1,206,066.86 美元。此次交易使其持股减少了 7.78%。该交易已在提交给证券交易委员会的文件中披露，相关文件可在此链接查看。此外，首席财务官 James Rodberg 于 1 月 5 日星期一出售了 4,405 股公司的股票。股票以平均价格 7.82 美元出售，总交易额为 34,447.10 美元。出售完成后，首席财务官持有 154,440 股公司的股票，价值 1,207,720.80 美元。此次交易使其持股减少了 2.77%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去一个季度中，内部人士共出售了 126,092 股公司股票，价值 970,005 美元。公司内部人士持有公司 30.90% 的股票。</p>
<h2>机构投资者对 Sight Sciences 的看法</h2>
<p>大型投资者最近增加或减少了在该公司的股份。KCK LTD. 在第二季度购买了 Sight Sciences 的新股份，价值 18,069,000 美元。Long Focus Capital Management LLC 在第三季度将其在 Sight Sciences 的股份增加了 1.3%。Long Focus Capital Management LLC 现在持有公司 3,193,305 股股票，价值 10,985,000 美元，此前在上个季度又购买了 41,797 股。先锋集团在第三季度将其在 Sight Sciences 的股份增加了 5.7%。先锋集团现在持有公司 1,906,696 股股票，价值 6,559,000 美元，此前在上个季度又购买了 102,609 股。Americana Partners LLC 在第三季度将其在 Sight Sciences 的股份增加了 42.4%。Americana Partners LLC 现在持有公司 1,229,819 股股票，价值 4,231,000 美元，此前在上个季度又购买了 365,901 股。最后，B Group Inc. 在第二季度将其在 Sight Sciences 的持股增加了 11.6%。B Group Inc. 现在持有公司 930,000 股股票，价值 3,841,000 美元，此前在该期间又收购了 96,400 股。机构投资者持有公司 55.51% 的股票。</p>
<h2>Sight Sciences 股票下跌 4.6%</h2>
<p>纳斯达克：SGHT 周五开盘价为 7.18 美元。该股票的 50 日简单移动平均线为 7.66 美元，200 日简单移动平均线为 5.19 美元。Sight Sciences 的 52 周最低价为 2.03 美元，52 周最高价为 9.24 美元。该公司的市值为 3.7961 亿美元，市盈率为-7.98，贝塔值为 2.42。该公司的债务与股本比率为 0.62，速动比率为 8.93，流动比率为 9.60。</p>
<p>Sight Sciences（纳斯达克：SGHT - 获取免费报告）最近于 9 月 8 日星期三发布了季度财报。该公司报告本季度每股收益为（0.81 美元）。Sight Sciences 的股本回报率为-61.59%，净利润率为-60.63%。该公司本季度的收入为 1254 万美元。平均而言，卖方分析师预计 Sight Sciences 在当前财政年度将发布-0.99 的每股收益。</p>
<h2>Sight Sciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Sight Sciences, Inc 是一家医疗设备公司，专注于开发和商业化微创治疗慢性眼病的产品。公司的旗舰产品包括 OMNI® 外科系统，旨在解决眼睛自然排水通道中的多个阻力点，以降低青光眼患者的眼内压，以及 TearCare® 系统，这是一种可穿戴设备，通过针对性的热脉冲治疗来治疗睑板腺功能障碍和干眼病。</p>
<p>自 2012 年成立并在纳斯达克上市以来，Sight Sciences 一直在追求将研究驱动的产品开发与直接销售模式相结合的战略。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Sight Sciences 更好</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护您的财富</li>
<li>市场恐慌：特朗普刚刚对您的股票投下了一颗炸弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Sight Sciences 吗？</h2>
<p>在考虑 Sight Sciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Sight Sciences 并不在名单上。</p>
<p>虽然 Sight Sciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SGHT

<p>Sight Sciences, Inc.（纳斯达克代码：SGHT）获得了八位分析师的 “持有” 共识评级。平均目标价为 8.30 美元，其中包括一项卖出、三项持有和四项买入建议。最近的目标价包括瑞银将其上调至 12.00 美元，花旗集团上调至 9.10 美元。内部人士的卖出包括执行副总裁 Brenton Taylor 和首席财务官 James Rodberg。机构投资者持有该股票的 55.51%。该股票目前下跌 4.6%，交易价格为 7.18 美元，市值为 3.7961 亿美元，市盈率为-7.98。公司在上个季度报告每股亏损 0.81 美元</p>

<p>Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) has been assigned a consensus recommendation of &#34;Hold&#34; from the eight analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.30.</p>
<div class="lb-trans"><p>Sight Sciences, Inc.（纳斯达克代码：SGHT - 获取免费报告）在目前覆盖该公司的八位分析师中获得了一致的 “持有” 推荐，Marketbeat Ratings 报告称。一位投资分析师对该股票给予了卖出推荐，三位分析师给予了持有推荐，四位分析师对该公司发布了买入推荐。在过去一年中，发布报告的券商对该股票的平均十二个月目标价为 8.30 美元。</p>
</div><p>Get <strong>Sight Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sight Sciences</strong> 的提醒：</p>
</div><p>Several brokerages have issued reports on SGHT. UBS Group lifted their price target on shares of Sight Sciences from $7.00 to $12.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, December 23rd. Citigroup lifted their target price on Sight Sciences from $5.50 to $9.10 and gave the company a &#34;neutral&#34; rating in a research report on Thursday, December 11th. Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Sight Sciences in a research report on Monday, December 29th. Morgan Stanley boosted their price target on Sight Sciences from $6.00 to $8.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Tuesday, December 2nd. Finally, Lake Street Capital upped their price objective on Sight Sciences from $5.00 to $7.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, October 21st.</p>
<div class="lb-trans"><p>几家券商已对 SGHT 发布了报告。瑞银集团将 Sight Sciences 的目标价从 7.00 美元上调至 12.00 美元，并在 12 月 23 日的研究报告中给予该公司 “买入” 评级。花旗集团将 Sight Sciences 的目标价从 5.50 美元上调至 9.10 美元，并在 12 月 11 日的研究报告中给予该公司 “中性” 评级。Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 Sight Sciences 的 “卖出（e+）” 评级。摩根士丹利在 12 月 2 日的研究报告中将 Sight Sciences 的目标价从 6.00 美元上调至 8.00 美元，并给予该股票 “等权重” 评级。最后，Lake Street Capital 在 10 月 21 日的研究报告中将 Sight Sciences 的目标价从 5.00 美元上调至 7.00 美元，并给予该股票 “买入” 评级。</p>
</div><p><strong>Read Our Latest Report on Sight Sciences</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Sight Sciences 的最新报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other news, EVP Brenton Taylor sold 14,418 shares of the business's stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $7.06, for a total transaction of $101,791.08. Following the transaction, the executive vice president directly owned 170,831 shares in the company, valued at $1,206,066.86. The trade was a 7.78% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, CFO James Rodberg sold 4,405 shares of the firm's stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $7.82, for a total transaction of $34,447.10. Following the completion of the sale, the chief financial officer owned 154,440 shares of the company's stock, valued at $1,207,720.80. This trade represents a 2.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 126,092 shares of company stock worth $970,005. Corporate insiders own 30.90% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，执行副总裁 Brenton Taylor 于 11 月 17 日星期一出售了 14,418 股公司的股票。股票以平均价格 7.06 美元出售，总交易额为 101,791.08 美元。交易后，这位执行副总裁直接持有公司 170,831 股股票，价值 1,206,066.86 美元。此次交易使其持股减少了 7.78%。该交易已在提交给证券交易委员会的文件中披露，相关文件可在此链接查看。此外，首席财务官 James Rodberg 于 1 月 5 日星期一出售了 4,405 股公司的股票。股票以平均价格 7.82 美元出售，总交易额为 34,447.10 美元。出售完成后，首席财务官持有 154,440 股公司的股票，价值 1,207,720.80 美元。此次交易使其持股减少了 2.77%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去一个季度中，内部人士共出售了 126,092 股公司股票，价值 970,005 美元。公司内部人士持有公司 30.90% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Sight Sciences</h2>
<div class="lb-trans"><h2>机构投资者对 Sight Sciences 的看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the business. KCK LTD. bought a new position in Sight Sciences during the second quarter worth $18,069,000. Long Focus Capital Management LLC lifted its stake in shares of Sight Sciences by 1.3% during the 3rd quarter. Long Focus Capital Management LLC now owns 3,193,305 shares of the company's stock worth $10,985,000 after buying an additional 41,797 shares during the last quarter. Vanguard Group Inc. grew its stake in Sight Sciences by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,906,696 shares of the company's stock valued at $6,559,000 after buying an additional 102,609 shares during the last quarter. Americana Partners LLC grew its stake in Sight Sciences by 42.4% in the 3rd quarter. Americana Partners LLC now owns 1,229,819 shares of the company's stock valued at $4,231,000 after buying an additional 365,901 shares during the last quarter. Finally, B Group Inc. raised its holdings in Sight Sciences by 11.6% in the 2nd quarter. B Group Inc. now owns 930,000 shares of the company's stock valued at $3,841,000 after acquiring an additional 96,400 shares during the period. Institutional investors own 55.51% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了在该公司的股份。KCK LTD. 在第二季度购买了 Sight Sciences 的新股份，价值 18,069,000 美元。Long Focus Capital Management LLC 在第三季度将其在 Sight Sciences 的股份增加了 1.3%。Long Focus Capital Management LLC 现在持有公司 3,193,305 股股票，价值 10,985,000 美元，此前在上个季度又购买了 41,797 股。先锋集团在第三季度将其在 Sight Sciences 的股份增加了 5.7%。先锋集团现在持有公司 1,906,696 股股票，价值 6,559,000 美元，此前在上个季度又购买了 102,609 股。Americana Partners LLC 在第三季度将其在 Sight Sciences 的股份增加了 42.4%。Americana Partners LLC 现在持有公司 1,229,819 股股票，价值 4,231,000 美元，此前在上个季度又购买了 365,901 股。最后，B Group Inc. 在第二季度将其在 Sight Sciences 的持股增加了 11.6%。B Group Inc. 现在持有公司 930,000 股股票，价值 3,841,000 美元，此前在该期间又收购了 96,400 股。机构投资者持有公司 55.51% 的股票。</p>
</div><h2>Sight Sciences Stock Down 4.6%</h2>
<div class="lb-trans"><h2>Sight Sciences 股票下跌 4.6%</h2>
</div><p>NASDAQ:SGHT opened at $7.18 on Friday. The stock has a 50-day simple moving average of $7.66 and a 200 day simple moving average of $5.19. Sight Sciences has a 52-week low of $2.03 and a 52-week high of $9.24. The company has a market cap of $379.61 million, a PE ratio of -7.98 and a beta of 2.42. The company has a debt-to-equity ratio of 0.62, a quick ratio of 8.93 and a current ratio of 9.60.</p>
<div class="lb-trans"><p>纳斯达克：SGHT 周五开盘价为 7.18 美元。该股票的 50 日简单移动平均线为 7.66 美元，200 日简单移动平均线为 5.19 美元。Sight Sciences 的 52 周最低价为 2.03 美元，52 周最高价为 9.24 美元。该公司的市值为 3.7961 亿美元，市盈率为-7.98，贝塔值为 2.42。该公司的债务与股本比率为 0.62，速动比率为 8.93，流动比率为 9.60。</p>
</div><p>Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its quarterly earnings results on Wednesday, September 8th. The company reported ($0.81) earnings per share for the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%.The business had revenue of $12.54 million for the quarter. On average, sell-side analysts expect that Sight Sciences will post -0.99 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Sight Sciences（纳斯达克：SGHT - 获取免费报告）最近于 9 月 8 日星期三发布了季度财报。该公司报告本季度每股收益为（0.81 美元）。Sight Sciences 的股本回报率为-61.59%，净利润率为-60.63%。该公司本季度的收入为 1254 万美元。平均而言，卖方分析师预计 Sight Sciences 在当前财政年度将发布-0.99 的每股收益。</p>
</div><h2>Sight Sciences Company Profile</h2>
<div class="lb-trans"><h2>Sight Sciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company's flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye's natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.</p>
<div class="lb-trans"><p>Sight Sciences, Inc 是一家医疗设备公司，专注于开发和商业化微创治疗慢性眼病的产品。公司的旗舰产品包括 OMNI® 外科系统，旨在解决眼睛自然排水通道中的多个阻力点，以降低青光眼患者的眼内压，以及 TearCare® 系统，这是一种可穿戴设备，通过针对性的热脉冲治疗来治疗睑板腺功能障碍和干眼病。</p>
</div><p>Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.</p>
<div class="lb-trans"><p>自 2012 年成立并在纳斯达克上市以来，Sight Sciences 一直在追求将研究驱动的产品开发与直接销售模式相结合的战略。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Sight Sciences</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Do not delete, read immediately</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Sight Sciences 更好</li>
<li>华尔街股票挑选者评选 2026 年第一只股票</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护您的财富</li>
<li>市场恐慌：特朗普刚刚对您的股票投下了一颗炸弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=SGHT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Sight Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Sight Sciences 吗？</h2>
</div><p>Before you consider Sight Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Sight Sciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Sight Sciences 并不在名单上。</p>
</div><p>While Sight Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sight Sciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Sight Sciences, Inc.（NASDAQ 代码：SGHT）被券商给予 “持有” 的平均评级